MURAGAKI Yoshihiro
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Visiting Professor |
|
Article types | Original article |
Language | English |
Peer review | Peer reviewed |
Title | Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. |
Journal | Formal name:Journal of neurosurgery Abbreviation:J Neurosurg ISSN code:00223085 |
Volume, Issue, Page | 121(3),pp.543-553 |
Author and coauthor | ISHIKAWA Eiichi†, MURAGAKI Yoshihiro, YAMAMOTO Tetsuya, MARUYAMA Takashi, TSUBOI Koji, IKUTA Soko, HASHIMOTO Koichi, UEMAE Youji, ISHIHARA Takeshi, MATSUDA Masahide, MATSUTANI Masao, KARASAWA Katsuyuki, NAKAZATO Yoichi, ABE Tatsuya, OHNO Tadao, MATSUMURA Akira |
Publication date | 2014/09 |
Summary | Temozolomide (TMZ) may enhance antitumor immunity in patients with glioblastoma multiforme (GBM). In this paper the authors report on a prospective Phase I/IIa clinical trial of fractionated radiotherapy (FRT) concomitant with TMZ therapy, followed by treatment with autologous formalin-fixed tumor vaccine (AFTV) and TMZ maintenance in patients with newly diagnosed GBM. |
DOI | 10.3171/2014.5.jns132392 |
Document No. | 24995786 |